WO2015170827A1 - Procédé de production d'un cristal de silodosine de forme gamma - Google Patents

Procédé de production d'un cristal de silodosine de forme gamma Download PDF

Info

Publication number
WO2015170827A1
WO2015170827A1 PCT/KR2015/003252 KR2015003252W WO2015170827A1 WO 2015170827 A1 WO2015170827 A1 WO 2015170827A1 KR 2015003252 W KR2015003252 W KR 2015003252W WO 2015170827 A1 WO2015170827 A1 WO 2015170827A1
Authority
WO
WIPO (PCT)
Prior art keywords
silodosin
crystals
crystal
formula
type
Prior art date
Application number
PCT/KR2015/003252
Other languages
English (en)
Korean (ko)
Inventor
이윤석
김유림
주준호
이재헌
장영길
Original Assignee
한미정밀화학주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미정밀화학주식회사 filed Critical 한미정밀화학주식회사
Publication of WO2015170827A1 publication Critical patent/WO2015170827A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom

Definitions

  • the present invention relates to a method for producing gamma-type crystals of silodosin safely and efficiently.
  • Prostatic hyperplasia is a high frequency disease in elderly men. 70% of men in their 60s suffer from the disease. Recently, as aging accelerates, the number of patients with prostatic hyperplasia is increasing rapidly, and interest in its treatment is also increasing.
  • the main treatment methods for prostatic hyperplasia include pharmacotherapy and surgery. Surgical treatments include laparotomy, transurethral prostatectomy (TUR-P), high temperature therapy, laser therapy, and stent placement.
  • TUR-P transurethral prostatectomy
  • As pharmacotherapy ⁇ -adrenergic receptor blocking drugs, anti-androgen drugs, herbal medicines and the like are known.
  • si lodosin one of the ⁇ ⁇ adrenergic receptor antagonists
  • Polymorphism refers to a phenomenon in which two or more crystalline forms are formed for a single compound. Although the same compounds have different crystalline forms, they show differences in water mechanical properties such as solubility, melting point and stability. In general, amorphous forms are often unsuitable for use in medicine because they have high solubility but low stability and high hygroscopic properties. On the other hand, crystalline forms have relatively low solubility problems but have high stability and low hygroscopicity. It has an advantage. Therefore, in the case of raw drug products, if there is no problem in solubility, it is preferable to prepare a crystalline form.
  • Crystals characterized by the principal peaks of 2 ⁇ equal to 7.0 ⁇ 0.2 ° , 12.5 ⁇ 0 2 ° , 18.5 ⁇ 0.2 °, 19.5 ⁇ 0.2 °, 20.7 ⁇ 0.2 °, and 21.1 ⁇ 0.2 ° ); And (3) Crystals characterized by the principal peaks of 2 ⁇ being 6.0 ⁇ 0.2 °, 10.6 ⁇ 0.2 °, 12.6 ⁇ 0.2 ° , 17.1 ⁇ 0.2 ° , 17.9 ⁇ 0.2 ° , 20.7 ⁇ 0.2 ° and 23.7 ⁇ 0.2 ° called ⁇ -type crystals).
  • the ⁇ -type crystals may be prepared by recrystallization of crude crystals using ethyl acetate, ethyl formate, acetone, methyl ethyl ketone, acetonitrile, tetrahydrofuran, acetone / acetonitrile (1: 1) mixed solvent, and the like.
  • ⁇ -type crystals can be prepared by dissolving crude crystals in an appropriate amount of methanol, and then petroleum ether and shaking them vigorously to precipitate crystals. : 4)
  • the disclosed ⁇ -form crystal is due to the volume of the crystallization solvent, the nature of the production process size to obtain a required capacity of the production equipment it is difficult to determine certain disadvantages ⁇ 'i.
  • it is easy to form homogeneous crystals with low volume of crystallization solvent but since the use of toluene as the crystallization solvent, long drying time is required to remove high boiling point of luluene below the standard of 890PPII1 (ICH guideline). There is a problem that it is necessary and difficult to completely remove the residual solvent.
  • X-type crystals can be obtained only by using luluene as the crystallization solvent, and thus, it is highly likely that luluene remains in the active ingredient of pharmaceuticals, meeting the market expectations for high purity and high quality raw materials. There is a problem that cannot be done. Therefore, if the problem is solved, other properties having excellent properties similar to those of ⁇ -type crystals
  • the crystalline form can be used in pharmaceuticals, there is an advantage that can be selected in the formulation development process suitable for the finished drug manufacturing process.
  • EP 2474529 discloses the crystal forms of syldoscin ( ⁇ type) and the 2 ⁇ of 3.1, 4.8, 6.28.9 and 2 ⁇ having main peaks of 6.6, 10.5, 13.1, 21.3 and 22.8 in powder X-ray diffraction patterns.
  • the crystal form of epsilonsin (epsilon form) which has a major peak of 11.6, is disclosed.
  • the epsilon form crystal has improved solubility compared with the three existing crystal forms.
  • the equilibrium concentration difference after 60 minutes is not very large, and in case of stability, it refers to the transition between crystalline forms, and does not mention the change in purity through stability test.
  • the present inventors have developed a method for producing a silodosin Y-type crystal using alcohol and a seed, which has been studied for a safer and more efficient method for producing a silodosin ⁇ -type crystal.
  • SUMMARY OF THE INVENTION Accordingly, it is an object of the present invention to provide a method for safely and efficiently producing a silodosin Y crystal.
  • the present invention comprises the steps of (1) dissolving silodosin in an alcohol solvent; (2) seeding the silodosin ⁇ type crystal while precipitating the solution to precipitate the crystal; And (3) filtering and drying the precipitated crystals, to provide a method for producing a silodosin Y-type crystal.
  • the production method of the silodosin Y crystal according to the present invention is safe because it does not use toluene, which is harmful to the human body, and the amount of alcohol used in the preparation is relatively small. Therefore, it is not only suitable for mass production and environmentally friendly, but also capable of producing products of constant quality and homogeneous crystals.
  • 1 is a graph showing the results of X-ray diffraction analysis (XRD) of the silodosin ⁇ -type crystal of the formula (1) according to the present invention.
  • FIG. 2 is a graph showing the differential scanning calorimetry (DSC) results of the silodosin ⁇ -type crystal of Formula 1 according to the present invention.
  • DSC differential scanning calorimetry
  • the method for producing a silodosin ⁇ -type crystallization method comprises the steps of: (1) dissolving silodosin in alcohol; (2) seeding the silodosin ⁇ -type crystal while precipitating the solution to precipitate the crystal; And (3) filtering and drying the precipitated crystals.
  • the starting material silodosin may be a silodosin crude crystal or crystal.
  • examples of the alcohol solvent for dissolving the silodosin include ethane,
  • 2-propane may be used.
  • the solvent may be used in an amount of 0.5 to 100 mL, preferably in an amount of 3 to 30 mL, based on 1 g of silodosin of Formula 1, which is a starting material.
  • the amount of solvent described above should be used in an amount of 100 mL or less based on l g of silodosin to prevent a decrease in yield.
  • dissolution of the silodosin can be carried out in a temperature range of 30 ° C to 100 ° C, preferably 40 ° C to 80 ° C.
  • step (2) crystallization is performed by seeding the silodosin ⁇ -type crystal while subjecting the solution of the step (1).
  • the crystallization may be carried out at -20 to 40 ° C, preferably 0 to 30 ° C, more preferably 10 to 20 ° C, it should be carried out at 40 ° C or less to prevent yield reduction.
  • the crystallization may be carried out at the above-mentioned temperature for 0.5 hours to 48 hours, preferably 1 hour to 24 hours.
  • the silodosin ⁇ -type crystals seeding for crystallization are commercially available or prepared by other methods, from 0.01 to 50 g, preferably 1, based on 100 g of the starting material silodosin. To 10 g.
  • the precipitated crystals are filtered and dried. The filtration and drying can be carried out according to methods well known in the pharmaceutical art.
  • Example 1 Preparation of ⁇ -type Crystals of Silodosin (Formula 1) After 2-propanol (100 mL) was added to silodosin (10.Og; Formula 1; Hanmi Fine Chemical), the mixture was heated to 50 ° C. and dissolved. . The solution was slowly angled to 20 ° C. and seeded with silodosin Y-type crystals (0.3 g) (Hanmi Chemical), followed by stirring at 3 ° C. and 5 ° C. for 2 hours at the same temperature. The resulting solid was filtered, washed with 2-propanol (10 mL) and dried to give white silodosin ⁇ type crystals (8.3 g, 80%; Formula 1).
  • the structure of the silodosin was analyzed using a nuclear magnetic resonance spectrum (NMR) 400 ⁇ z FT-NMR Spectrometer (Varian, 400-MR).
  • Example 2 Preparation of ⁇ -type crystals of silodosin (Formula 1) After adding 1-butanol (100 mL) to silodosin (10.Og; Formula 1), the mixture was heated to 45 ° C. and dissolved. It was. The solution was slowly angled to 20 ° C. and seeded with silodosin ⁇ -type crystals (0.5 g), followed by stirring at 3 ° C. and 5 ° C. for 2 hours at the same temperature.
  • Example 3 Preparation of ⁇ -type crystals of silodosin (Formula 1) 2-butanol (100 mL) was added to silodosin (10. Og; Formula 1), and then dissolved by heating at 45 ° C. The solution was slowly decanted with 2 (rc and seeded with silodosin ⁇ -type crystals (0,5 g) and stirred for 3 hours at the same temperature and 2 hours at 5 ° C.
  • Example 4 Preparation of ⁇ -type crystals of silodosin (Formula 1) To propane (10. Og; Formula 1), 2-propane and a mixed solvent of 2-butanol (1: 1; 140 mL) were added, and then dissolved by raising the temperature to 40 ° C. The solution was washed with 20 ° C. After cooling slowly and seeding the silodosin ⁇ -type crystals (0.3 g), the mixture was stirred at the same temperature for 3 hours at 2 ° C.
  • Example 6 Preparation of ⁇ -type crystals of silodosin (Formula 1) After t-butane (120 mL) was added to silodosin (lO.Og; Formula 1), the solution was dissolved by heating at 40 ° C. The solution was slowly angled to 20 ° C. and seeded with silodosin ⁇ -type crystals (0.3 g), followed by stirring at the same temperature for 3 hours.
  • XRD X-ray diffraction analysis
  • DSC differential scanning calorimetry
  • METLER TOLEDO differential scanning calorimeter

Abstract

La présente invention concerne un procédé de production d'un cristal de silodosine de forme γ, et le procédé de production d'un cristal de silodosine de forme γ selon la présente invention présente les avantages d'être sans risque du fait de la non utilisation de toluène, qui est nocif pour le corps humain ; d'être adapté à la production de masse et respectueux de l'environnement étant donné que la quantité d'alcool utilisée dans la production est relativement faible ; et d'être susceptible de produire un produit de qualité uniforme et un cristal homogène.
PCT/KR2015/003252 2014-05-08 2015-04-01 Procédé de production d'un cristal de silodosine de forme gamma WO2015170827A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140054634A KR20150127996A (ko) 2014-05-08 2014-05-08 실로도신 감마형 결정의 제조방법
KR10-2014-0054634 2014-05-08

Publications (1)

Publication Number Publication Date
WO2015170827A1 true WO2015170827A1 (fr) 2015-11-12

Family

ID=54392654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/003252 WO2015170827A1 (fr) 2014-05-08 2015-04-01 Procédé de production d'un cristal de silodosine de forme gamma

Country Status (2)

Country Link
KR (1) KR20150127996A (fr)
WO (1) WO2015170827A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101673160B1 (ko) * 2014-10-24 2016-11-07 보령제약 주식회사 실로도신 γ 결정형의 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022538A1 (fr) * 2002-09-06 2004-03-18 Kissei Pharmaceutical Co., Ltd. Cristal pour medicament solide a administration orale et medicament solide a administration orale destine au traitement de la dysurie contenant ce cristal
US7834193B2 (en) * 2004-10-27 2010-11-16 Kissei Pharmaceutical Co., Ltd. Indoline compound and process for producing the same
WO2012077138A1 (fr) * 2010-12-09 2012-06-14 Panacea Biotec Limited Procédés de cristallisation du (r)-1-(3-hydroxypropyl)-5-[2-[2-(2,2,2- trifluoroéthoxy)phénoxy]éthylamino]propyl]indoline-7-carboxamide
WO2015093456A1 (fr) * 2013-12-17 2015-06-25 東和薬品株式会社 Cristal de silodosine de forme γ et son procédé de production

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022538A1 (fr) * 2002-09-06 2004-03-18 Kissei Pharmaceutical Co., Ltd. Cristal pour medicament solide a administration orale et medicament solide a administration orale destine au traitement de la dysurie contenant ce cristal
US7834193B2 (en) * 2004-10-27 2010-11-16 Kissei Pharmaceutical Co., Ltd. Indoline compound and process for producing the same
WO2012077138A1 (fr) * 2010-12-09 2012-06-14 Panacea Biotec Limited Procédés de cristallisation du (r)-1-(3-hydroxypropyl)-5-[2-[2-(2,2,2- trifluoroéthoxy)phénoxy]éthylamino]propyl]indoline-7-carboxamide
WO2015093456A1 (fr) * 2013-12-17 2015-06-25 東和薬品株式会社 Cristal de silodosine de forme γ et son procédé de production

Also Published As

Publication number Publication date
KR20150127996A (ko) 2015-11-18

Similar Documents

Publication Publication Date Title
WO2016184436A1 (fr) Nouvelle forme cristalline de sel de méthanesulfonate de lenvatinib et son procédé de préparation
RU2631321C2 (ru) Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения
WO2003008408A1 (fr) Polymorphe de norastemizole antihistaminique
BR122018014454B1 (pt) forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
EP2297092A1 (fr) Formes polymorphes et amorphes de lacosamide et compositions amorphes
CN110831930B (zh) 杂环亚基乙酰胺衍生物的晶体
JP2021527043A (ja) 新規の塩および結晶
JP7369769B2 (ja) アミノピリミジン誘導体又はその塩を含む経口投与用医薬組成物
JP2019104760A (ja) ベンズイミダゾール誘導体の新規結晶形及びその製造方法
CA2912902A1 (fr) Formes polymorphiques de chlorhydrate de nilotinib
WO2018122780A1 (fr) Formes solides de mésylate de lenvatinib
WO2010129636A2 (fr) Lénalidomide polymorphe
JP2018516946A (ja) ヒストン脱アセチル化阻害剤の結晶形態
WO2015170827A1 (fr) Procédé de production d'un cristal de silodosine de forme gamma
WO2018015974A1 (fr) Formes polymorphes de sélexipag et dispersion solide amorphe de sélexipag
JP2009102356A (ja) 新規な結晶構造を有するエリスロマイシン誘導体及びその製造方法
WO2016172333A1 (fr) Forme à l'état solide de pérampanel
WO2012127493A1 (fr) Formes polymorphes de lénalidomide
CN117510418A (zh) 结晶
EA004950B1 (ru) Аморфная модификация торасемида
TWI324517B (en) 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo[2,3d]pyrimidine hydrogen mesylate and its polymorphic forms
TW202019871A (zh) 稠合三環γ-胺基酸衍生物鹽類之晶型、製備方法及其用途
EP3004104A1 (fr) Forme cristalline de n,n-dicyclopropyl-4-(1,5-diméthyl-1h-pyrazol-3-ylamino)-6-éthyl-1-méthyl-1,6-dihydro-imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide pour le traitement de troubles myéloprolifératifs
WO2014013511A2 (fr) Dispersion solide de rufinamide
AU693939B2 (en) Novel crystal forms of 1-(5-methanesulfonamidoindolyl-2- carbonyl)-4-(3-(1-methylethylamino)-2-pyridinyl) piperazine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15789842

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15789842

Country of ref document: EP

Kind code of ref document: A1